4.2 Article

Analyzing the differentially expressed genes and pathway cross-talk in aggressive breast cancer

Journal

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
Volume 41, Issue 1, Pages 132-140

Publisher

WILEY
DOI: 10.1111/jog.12495

Keywords

aggressive breast cancer; function enrichment analysis; pathway cross-talk analysis

Ask authors/readers for more resources

AimThe aim of this study was to explore the genes and pathways involved in the aggressive breast cancer cells. MethodsThe gene expression profiles of GSE40057, including four aggressive breast cell lines and six less aggressive cell lines, were downloaded from the Gene Expression Omnibus (GEO) database. The gene differential expression analysis was carried out with limma software with the method of Bayes for multiple tests. The gene ontology (GO) term enrichment and pathway cross-talk analysis were performed with the online tool of DAVID and Cytoscape software. ResultsA total of 401 differentially expressed genes (DEG), such as pentraxin 3 (PTX3), snail family zinc finger 2 (SNAI2), interleukin-8/6 (IL-8/6), osteonectin (SPARC), matrix metallopeptidase-1 (MMP-1) and Ras-related protein Rab-25 (Rab 25), were identified between aggressive and less aggressive cell lines. They were mainly enriched in the GO terms of response to wounding, negative regulation of cell proliferation and calcium binding. Pathways in cancer dysfunctionally interacted with glyoxylate and dicarboxylate metabolism (P<0.0001), basal transcription factors (P<0.0001), tyrosine metabolism (P<0.0001), calcium signaling pathway (P=0.0021), FcR-mediated phagocytosis (P=0.0022), metabolism of xenobiotics by cytochrome P450 (P=0.0097) and phagosome (P=0.0102). ConclusionThe screened aggressive cancer-associated DEG (PTX3, SNAI2, IL-8/6, SPARC, MMP-1 and Rab25) and significant pathways (calcium signaling pathway, tyrosine metabolism, alanine, aspartate and glutamate metabolism) give us new insights into the mechanism of aggressive breast cancer cells, and these DEG may become promising target genes in the treatment of metastatic breast cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available